keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CKLF1-C27 TFA, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 TFA can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 TFA shows great effect on promoting proliferation on HUVECs. CKLF1-C27 TFA has the potential for psoriasis research [1] .
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | CKLF1-C27 TFA, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 TFA can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 TFA shows great effect on promoting proliferation on HUVECs. CKLF1-C27 TFA has the potential for psoriasis research [1] . |
Molecular Weight | 3310.8 |
Formula | C153H244F3N39O39 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CKLF1-C27 TFA inhibitor inhibit